discussion response from this post.

According to the supplied Proforma, providing the specialty pharmacy service is feasible. The expected gross revenue gradually rises, from $69.75 million in 2017 to $232.5 million in 2021, demonstrating significant financial growth. While the expenses of products sold grow, the EBITDA margin increases, reaching $17.62 million by 2021. The specialty pharmacy service displays solid financial planning, as seen by the established sales, general, and administrative (SG&A) costs, with controllable inflation rates over the forecast ones. The alignment of income and costs demonstrates a deliberate approach to controlling operational expenses while being profitable (Shi, 2021). Such fiscal responsibility is required to continue the provision of a large-scale service in a competitive and heavily regulated healthcare industry. However, while economic estimates indicate that the service is a good investment, it is necessary to carefully evaluate external issues. For example, market rivalry might impact revenue growth by increasing pricing pressures, while regulatory problems could raise compliance costs or cause delays. Addressing these hazards necessitates proactive measures, such as ongoing market monitoring and investments in legal compliance infrastructure. If the business successfully mitigates these outside threats, the specialty pharmacy service will be well-positioned for long-term prosperity, providing benefits to clients and other partners, while maintaining its financial stability.

Reference

Shi, W. (2021). Analyzing enterprise asset structure and profitability using cloud computing and strategic management accounting. PLoS ONE, 16(9), Article e0257826.https://doi.org/10.1371/journal.pone.0257826